binimetinib

Summary

Name(s) Target Manufacturer Status
binimetinib MAP2K1, MAP2K2 Array BioPharma Investigational

Clinical Trials

Trial Drug Status Phase
Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma [NCT01909453] LGX818, Zelboraf, binimetinib Recruiting Phase 3
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma [NCT01763164] Dacarbazine, binimetinib Recruiting Phase 3
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma [NCT01820364] BGJ398, INC280, LEE011, LGX818, binimetinib, buparlisib Recruiting Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors [NCT01885195] binimetinib Recruiting Phase 2
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma [NCT02159066] BGJ398, INC280, LEE011, LGX818, binimetinib, buparlisib Recruiting Phase 2
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma [NCT01801358] binimetinib, sotrastaurin Recruiting Phase 1/Phase 2
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors [NCT01543698] LEE011, LGX818, binimetinib Recruiting Phase 1/Phase 2
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma [NCT01781572] LEE011, binimetinib Recruiting Phase 1/Phase 2
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors [NCT01449058] BYL719, binimetinib Recruiting Phase 1/Phase 2
#